BioCentury | Dec 14, 2018
Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
BioCentury | Aug 19, 2013
Clinical News

CPX-351: Clinical trial started

Celator said investigators at the Fred Hutchinson Cancer Research Center began an open-label clinical trial to evaluate 32 and 64 units/m 2 IV CPX-351 in up to 90 high-risk patients with untreated MDS or AML...
BioCentury | Jun 14, 2010
Clinical News

Mapatumumab: Phase II data

...Business: Cancer Molecular target: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) Description: TRM-1...
BioCentury | Mar 22, 2010
Clinical News

Mapatumumab: Phase II data

...Business: Cancer Molecular target: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) Description: TRM-1...
BioCentury | Mar 18, 2010
Clinical News

HGSI reports mapatumumab data

...company plans to present full data this year at a scientific meeting. Mapatumumab is a TRM-1...
BioCentury | Dec 15, 2008
Clinical News

ATIR: Pivotal trial start

In early 2009, Kiadis will begin an international, pivotal trial (CR-AIR-004) in 60 patients with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) eligible for an allogeneic bone marrow transplant but...
BioCentury | Sep 8, 2008
Finance

Ebb & Flow

...mapatumumab) plus Velcade bortezomib from Takeda (Tokyo:4502) was comparable to bortezomib alone. HGS-ETR1 is a TRM-1...
BioCentury | Sep 8, 2008
Clinical News

Mapatumumab: Phase II data

...Business: Cancer Molecular target: Tumor necrosis factor-related apoptosis-inducing ligand receptor 1 ( TRAIL-R1 ) Description: TRM-1...
BioCentury | Sep 1, 2008
Clinical News

Mapatumumab: Completed Phase II enrollment

...Business: Cancer Molecular target: Tumor necrosis factor-related apoptosis-inducing ligand receptor 1 ( TRAIL-R1 ) Description: TRM-1...
BioCentury | Apr 21, 2008
Company News

Human Genome Sciences, GlaxoSmithKline, Kirin deal

...Genome rights to mapatumumab ( HGS-ETR1 ) and an option to lexatumumab (HGS-ETR2). Mapatumumab, a TRM-1...
Items per page:
1 - 10 of 42